Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-04

AUTHORS

K. Rašlová, D. Dubovská, V. Mongiellová, T. Trnovec

ABSTRACT

Objective: We examined the relationship between plasma levels of fenofibric acid, the active metabolite of fenofibrate, and differences in concentrations of plasma lipids, in subjects with primary type IIA or IIB hyperlipoproteinemia (HLP). Subjects and methods: Twenty-nine patients (13 with type IIA and 16 with type IIB HLP) were treated with a single daily 200-mg dose of micronized fenofibrate for 3␣months, after which the plasma levels of fenofibric acid were determined by HPLC after an overnight fast.Results: In the type IIA HLP phenotype, statistically significant correlations were found between fenofibric acid levels and changes in total cholesterol, LDL-C and apo-B at all three control visits, with the highest correlation coefficients at V3 visit (total cholesterol \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, LDL-C \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, apo-B \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}). In type IIB HLP, statistical significance was confirmed only when performing an analysis of pooled values for total cholesterol and LDL-C (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, respectively). The high correlation between plasma fenofibric acid levels and its effect on betalipoprotein changes might reflect the effect of fenofibrate on the catabolism of plasma LDL by the LDL receptor, since that type of relationship is typical of drugs which directly influence the target compartment without an effect on intermediary steps of metabolism. An explanation for the different levels of correlations in type IIA and IIB patients might be found in their different metabolic defects. The fact that fenofibrate's impact on VLDLs is such an important part of its effect on lipoprotein metabolism supports the concept that the effect of circulating fenofibric acid is less pronounced on the LDL receptor in type IIB HLP. More... »

PAGES

101-106

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050257

DOI

http://dx.doi.org/10.1007/s002280050257

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009854876

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9174678


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticholesteremic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apolipoproteins B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fenofibrate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperlipoproteinemia Type II", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypolipidemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Lipid and Glucose Metabolism, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republic Tel.: +421-7-3789238; Fax: +42-7-373906; e-mail raslova@upkm.sanet.sk, XX", 
          "id": "http://www.grid.ac/institutes/grid.9982.a", 
          "name": [
            "Department of Lipid and Glucose Metabolism, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republic Tel.: +421-7-3789238; Fax: +42-7-373906; e-mail raslova@upkm.sanet.sk, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ra\u0161lov\u00e1", 
        "givenName": "K.", 
        "id": "sg:person.01104325200.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104325200.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX", 
          "id": "http://www.grid.ac/institutes/grid.9982.a", 
          "name": [
            "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dubovsk\u00e1", 
        "givenName": "D.", 
        "id": "sg:person.01024106504.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024106504.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX", 
          "id": "http://www.grid.ac/institutes/grid.9982.a", 
          "name": [
            "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mongiellov\u00e1", 
        "givenName": "V.", 
        "id": "sg:person.01001460742.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001460742.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX", 
          "id": "http://www.grid.ac/institutes/grid.9982.a", 
          "name": [
            "Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbov\u00e1 14, SK-833 01 Bratislava, Slovak Republik, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trnovec", 
        "givenName": "T.", 
        "id": "sg:person.01226122167.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226122167.37"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1997-04", 
    "datePublishedReg": "1997-04-01", 
    "description": "Objective: We examined the relationship between plasma levels of fenofibric acid, the active metabolite of fenofibrate, and differences in concentrations of plasma lipids, in subjects with primary type IIA or IIB hyperlipoproteinemia (HLP). Subjects and methods: Twenty-nine patients (13 with type IIA and 16 with type IIB HLP) were treated with a single daily 200-mg dose of micronized fenofibrate for 3\u2423months, after which the plasma levels of fenofibric acid were determined by HPLC after an overnight fast.Results: In the type IIA HLP phenotype, statistically significant correlations were found between fenofibric acid levels and changes in total cholesterol, LDL-C and apo-B at all three control visits, with the highest correlation coefficients at V3 visit (total cholesterol \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym}\n\t\t\t\t\\usepackage{amsfonts}\n\t\t\t\t\\usepackage{amssymb}\n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}\\end{document}, LDL-C \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym}\n\t\t\t\t\\usepackage{amsfonts}\n\t\t\t\t\\usepackage{amssymb}\n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}\\end{document}, apo-B \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym}\n\t\t\t\t\\usepackage{amsfonts}\n\t\t\t\t\\usepackage{amssymb}\n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}\\end{document}). In type IIB HLP, statistical significance was confirmed only when performing an analysis of pooled values for total cholesterol and LDL-C (\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym}\n\t\t\t\t\\usepackage{amsfonts}\n\t\t\t\t\\usepackage{amssymb}\n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}\\end{document}, \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym}\n\t\t\t\t\\usepackage{amsfonts}\n\t\t\t\t\\usepackage{amssymb}\n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}\\end{document}, respectively). The high correlation between plasma fenofibric acid levels and its effect on betalipoprotein changes might reflect the effect of fenofibrate on the catabolism of plasma LDL by the LDL receptor, since that type of relationship is typical of drugs which directly influence the target compartment without an effect on intermediary steps of metabolism. An explanation for the different levels of correlations in type IIA and IIB patients might be found in their different metabolic defects. The fact that fenofibrate's impact on VLDLs is such an important part of its effect on lipoprotein metabolism supports the concept that the effect of circulating fenofibric acid is less pronounced on the LDL receptor in type IIB HLP.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050257", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "52"
      }
    ], 
    "keywords": [
      "type IIb hyperlipoproteinemia", 
      "IIb hyperlipoproteinemia", 
      "total cholesterol", 
      "plasma levels", 
      "acid levels", 
      "fenofibric acid", 
      "LDL receptor", 
      "effect of fenofibrate", 
      "primary type IIa", 
      "type IIa", 
      "different metabolic defects", 
      "control visits", 
      "lipoprotein cholesterol", 
      "primary hypercholesterolemia", 
      "IIB patients", 
      "plasma lipids", 
      "lipoprotein metabolism", 
      "plasma LDL", 
      "apolipoprotein B", 
      "hyperlipoproteinemia", 
      "metabolic defects", 
      "active metabolite", 
      "patients", 
      "LDL", 
      "fenofibrate", 
      "cholesterol", 
      "statistical significance", 
      "significant correlation", 
      "visits", 
      "pooled values", 
      "receptors", 
      "subjects", 
      "metabolism", 
      "IIA", 
      "levels", 
      "hypercholesterolemia", 
      "VLDL", 
      "dose", 
      "months", 
      "effect", 
      "drugs", 
      "correlation coefficient", 
      "correlation", 
      "high correlation", 
      "catabolism", 
      "phenotype", 
      "metabolites", 
      "changes", 
      "acid", 
      "target compartment", 
      "relationship", 
      "lipids", 
      "compartments", 
      "significance", 
      "differences", 
      "intermediary step", 
      "defects", 
      "impact", 
      "different levels", 
      "apo", 
      "concentration", 
      "important part", 
      "high correlation coefficient", 
      "HPLC", 
      "type of relationship", 
      "types", 
      "analysis", 
      "part", 
      "values", 
      "method", 
      "explanation", 
      "fact", 
      "step", 
      "concept", 
      "coefficient", 
      "type IIA HLP phenotype", 
      "IIA HLP phenotype", 
      "HLP phenotype", 
      "fenofibric acid levels", 
      "V3 visit", 
      "plasma fenofibric acid levels", 
      "betalipoprotein changes", 
      "fenofibrate's impact"
    ], 
    "name": "Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia", 
    "pagination": "101-106", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009854876"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050257"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9174678"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050257", 
      "https://app.dimensions.ai/details/publication/pub.1009854876"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_293.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050257"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050257'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050257'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050257'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050257'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      124 URIs      116 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050257 schema:about N053fef5488dd496390db1eec7f8fb990
2 N17ea36cf4d6e449e8b81d64948ebf62b
3 N1def10c03b0e410c80cfd9e63e9966ad
4 N4cc29a158bb54d5ea176b43f6630b469
5 N87b55939a9aa4d3a961f4c3105e56068
6 N93fc6b9df9ad4d20b95c2c52a79a8025
7 Na4f8be69db4c4e339a0f756fde1271b4
8 Nb05e0acc0b654f2bbe66b79dba3fb084
9 Nbaa2c4478047416ba61cd6bdc7a5c1c9
10 Nbd1d31fe46294cd7b050288d3a1e8601
11 Nbf9940af5f5e412283a7de1e236d5914
12 Nc0f229503e8945179a856226a040832f
13 Nd5a453f93d6d405bb1890122d23312a0
14 Nf793463b658a4659b30e53e8bb83beba
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Na3edcf8dfc54487b85846ca38abea93b
18 schema:datePublished 1997-04
19 schema:datePublishedReg 1997-04-01
20 schema:description Objective: We examined the relationship between plasma levels of fenofibric acid, the active metabolite of fenofibrate, and differences in concentrations of plasma lipids, in subjects with primary type IIA or IIB hyperlipoproteinemia (HLP). Subjects and methods: Twenty-nine patients (13 with type IIA and 16 with type IIB HLP) were treated with a single daily 200-mg dose of micronized fenofibrate for 3␣months, after which the plasma levels of fenofibric acid were determined by HPLC after an overnight fast.Results: In the type IIA HLP phenotype, statistically significant correlations were found between fenofibric acid levels and changes in total cholesterol, LDL-C and apo-B at all three control visits, with the highest correlation coefficients at V3 visit (total cholesterol \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, LDL-C \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, apo-B \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}). In type IIB HLP, statistical significance was confirmed only when performing an analysis of pooled values for total cholesterol and LDL-C (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}\end{document}, respectively). The high correlation between plasma fenofibric acid levels and its effect on betalipoprotein changes might reflect the effect of fenofibrate on the catabolism of plasma LDL by the LDL receptor, since that type of relationship is typical of drugs which directly influence the target compartment without an effect on intermediary steps of metabolism. An explanation for the different levels of correlations in type IIA and IIB patients might be found in their different metabolic defects. The fact that fenofibrate's impact on VLDLs is such an important part of its effect on lipoprotein metabolism supports the concept that the effect of circulating fenofibric acid is less pronounced on the LDL receptor in type IIB HLP.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N0596202b940d4f4da42c18a6dbd371d1
25 N144b88e5b3c745d182114197414458c2
26 sg:journal.1054337
27 schema:keywords HLP phenotype
28 HPLC
29 IIA
30 IIA HLP phenotype
31 IIB patients
32 IIb hyperlipoproteinemia
33 LDL
34 LDL receptor
35 V3 visit
36 VLDL
37 acid
38 acid levels
39 active metabolite
40 analysis
41 apo
42 apolipoprotein B
43 betalipoprotein changes
44 catabolism
45 changes
46 cholesterol
47 coefficient
48 compartments
49 concentration
50 concept
51 control visits
52 correlation
53 correlation coefficient
54 defects
55 differences
56 different levels
57 different metabolic defects
58 dose
59 drugs
60 effect
61 effect of fenofibrate
62 explanation
63 fact
64 fenofibrate
65 fenofibrate's impact
66 fenofibric acid
67 fenofibric acid levels
68 high correlation
69 high correlation coefficient
70 hypercholesterolemia
71 hyperlipoproteinemia
72 impact
73 important part
74 intermediary step
75 levels
76 lipids
77 lipoprotein cholesterol
78 lipoprotein metabolism
79 metabolic defects
80 metabolism
81 metabolites
82 method
83 months
84 part
85 patients
86 phenotype
87 plasma LDL
88 plasma fenofibric acid levels
89 plasma levels
90 plasma lipids
91 pooled values
92 primary hypercholesterolemia
93 primary type IIa
94 receptors
95 relationship
96 significance
97 significant correlation
98 statistical significance
99 step
100 subjects
101 target compartment
102 total cholesterol
103 type IIA HLP phenotype
104 type IIa
105 type IIb hyperlipoproteinemia
106 type of relationship
107 types
108 values
109 visits
110 schema:name Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia
111 schema:pagination 101-106
112 schema:productId N25f1f1eaac6247fd9f6abcf2e08e879e
113 Ne5961c06a036425aa67c8929473dee10
114 Ne93abc28dd764c96ae1de9be22f85f63
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009854876
116 https://doi.org/10.1007/s002280050257
117 schema:sdDatePublished 2021-12-01T19:10
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nc11d2a3f9e4c4870979dfe9bfb6bbb7d
120 schema:url https://doi.org/10.1007/s002280050257
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N053fef5488dd496390db1eec7f8fb990 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N0596202b940d4f4da42c18a6dbd371d1 schema:volumeNumber 52
128 rdf:type schema:PublicationVolume
129 N144b88e5b3c745d182114197414458c2 schema:issueNumber 2
130 rdf:type schema:PublicationIssue
131 N17ea36cf4d6e449e8b81d64948ebf62b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Drug Administration Schedule
133 rdf:type schema:DefinedTerm
134 N1def10c03b0e410c80cfd9e63e9966ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Fenofibrate
136 rdf:type schema:DefinedTerm
137 N25f1f1eaac6247fd9f6abcf2e08e879e schema:name doi
138 schema:value 10.1007/s002280050257
139 rdf:type schema:PropertyValue
140 N4cc29a158bb54d5ea176b43f6630b469 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Apolipoproteins B
142 rdf:type schema:DefinedTerm
143 N61e6311b459245a4853749a064c80a45 rdf:first sg:person.01001460742.34
144 rdf:rest N69cca2ed36c44e4bba7ca32a373033f6
145 N69cca2ed36c44e4bba7ca32a373033f6 rdf:first sg:person.01226122167.37
146 rdf:rest rdf:nil
147 N87b55939a9aa4d3a961f4c3105e56068 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Cholesterol
149 rdf:type schema:DefinedTerm
150 N93fc6b9df9ad4d20b95c2c52a79a8025 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Hyperlipoproteinemia Type II
152 rdf:type schema:DefinedTerm
153 Na3edcf8dfc54487b85846ca38abea93b rdf:first sg:person.01104325200.99
154 rdf:rest Na9cb9d796718458eb660e59256f004a9
155 Na4f8be69db4c4e339a0f756fde1271b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 Na9cb9d796718458eb660e59256f004a9 rdf:first sg:person.01024106504.39
159 rdf:rest N61e6311b459245a4853749a064c80a45
160 Nb05e0acc0b654f2bbe66b79dba3fb084 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 Nbaa2c4478047416ba61cd6bdc7a5c1c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Prospective Studies
165 rdf:type schema:DefinedTerm
166 Nbd1d31fe46294cd7b050288d3a1e8601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Anticholesteremic Agents
168 rdf:type schema:DefinedTerm
169 Nbf9940af5f5e412283a7de1e236d5914 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 Nc0f229503e8945179a856226a040832f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Cholesterol, LDL
174 rdf:type schema:DefinedTerm
175 Nc11d2a3f9e4c4870979dfe9bfb6bbb7d schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Nd5a453f93d6d405bb1890122d23312a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Hypolipidemic Agents
179 rdf:type schema:DefinedTerm
180 Ne5961c06a036425aa67c8929473dee10 schema:name dimensions_id
181 schema:value pub.1009854876
182 rdf:type schema:PropertyValue
183 Ne93abc28dd764c96ae1de9be22f85f63 schema:name pubmed_id
184 schema:value 9174678
185 rdf:type schema:PropertyValue
186 Nf793463b658a4659b30e53e8bb83beba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Middle Aged
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
193 schema:name Clinical Sciences
194 rdf:type schema:DefinedTerm
195 sg:journal.1054337 schema:issn 0031-6970
196 1432-1041
197 schema:name European Journal of Clinical Pharmacology
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01001460742.34 schema:affiliation grid-institutes:grid.9982.a
201 schema:familyName Mongiellová
202 schema:givenName V.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001460742.34
204 rdf:type schema:Person
205 sg:person.01024106504.39 schema:affiliation grid-institutes:grid.9982.a
206 schema:familyName Dubovská
207 schema:givenName D.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024106504.39
209 rdf:type schema:Person
210 sg:person.01104325200.99 schema:affiliation grid-institutes:grid.9982.a
211 schema:familyName Rašlová
212 schema:givenName K.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104325200.99
214 rdf:type schema:Person
215 sg:person.01226122167.37 schema:affiliation grid-institutes:grid.9982.a
216 schema:familyName Trnovec
217 schema:givenName T.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226122167.37
219 rdf:type schema:Person
220 grid-institutes:grid.9982.a schema:alternateName Department of Lipid and Glucose Metabolism, Institute of Preventive and Clinical Medicine, Limbová 14, SK-833 01 Bratislava, Slovak Republic Tel.: +421-7-3789238; Fax: +42-7-373906; e-mail raslova@upkm.sanet.sk, XX
221 Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbová 14, SK-833 01 Bratislava, Slovak Republik, XX
222 schema:name Department of Lipid and Glucose Metabolism, Institute of Preventive and Clinical Medicine, Limbová 14, SK-833 01 Bratislava, Slovak Republic Tel.: +421-7-3789238; Fax: +42-7-373906; e-mail raslova@upkm.sanet.sk, XX
223 Department of Pharmacokinetics, Institute of Preventive and Clinical Medicine, Limbová 14, SK-833 01 Bratislava, Slovak Republik, XX
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...